Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma.

Source: In Vivo - August 30, 2020 Category: Research Authors: KOBAYASHI, K., IIKURA, Y., HIRAIDE, M., YOKOKAWA, T., AOYAMA, T., SHIKIBU, S., HASHIMOTO, K., SUZUKI, K., SATO, H., SUGIYAMA, E., TAJIMA, M., HAMA, T. Tags: Clinical Studies Source Type: research